Parkman Healthcare Partners LLC Inozyme Pharma, Inc. Transaction History

Parkman Healthcare Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.14 - $7.66 $43,515 - $80,514	10,511 Added 4.95%	222,943 $1.71 Million
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $99,012 - $164,412	36,536 Added 20.77%	212,432 $904,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $29,063 - $49,742	7,106 Added 4.21%	175,896 $738,000
Q2 2023 Aug 11, 2023	BUY	$4.93 - $6.74 $215,884 - $295,144	43,790 Added 35.03%	168,790 $940,000
Q1 2023 May 12, 2023	BUY	$1.3 - $5.73 $162,500 - $716,250	125,000 New	125,000 $716,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $80.3M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.